In a federal lawsuit filed this week in Miami, Eli Lilly accused a network of mail-order pharmacies, wholesalers, and patient service groups tied to what it calls the largest Pentecostal denomination in the U.S. of defrauding it out of more than $200 million through a multi-year rebate scheme involving the diabetes drug Trulicity. The complaint names DrugPlace, Galaxy Pharmacy, and other companies, alleging they ran a “prescription cost share program” for members of the Church of God in Christ that submitted hundreds of thousands of false rebate claims for Trulicity that never reached patients. The drug, Lilly says, was later resold through affiliated wholesalers instead of being dispensed. When discovered, DrugPlace allegedly shut its Nashville pharmacy and began liquidating assets. Lilly is seeking a temporary restraining order, restitution of rebates, profits, and damages. The Church of God in Christ, not named as a defendant, said it had “no knowledge” of or involvement in the alleged actions.
The case exposes a weak point in the rebate and chargeback machinery that underpins U.S. drug pricing. According to Lilly’s narrative, the defendants exploited the manufacturer’s rebate payment system by fabricating patient-level dispensing data, essentially monetizing unused product and rebate flows. For manufacturers, that’s a warning: rebate validation, often handled by contracted PBMs and distributors, still leaves openings for coordinated fraud when intermediaries share ownership or data systems. For payers and PBMs, the question is who ultimately bears the loss when rebates are clawed back or deemed invalid, and that question remains unresolved.
The data from existing rebate audits is mixed, but pressure is clearly building for greater traceability in patient-level rebate verification and more federal oversight of secondary-market distribution chains. Lilly’s pursuit of both restitution and profit disgorgement signals a more aggressive posture, intended as a public deterrent and an internal message about pricing integrity in its diabetes portfolio. And for manufacturer compliance teams, this case lands like a cold reminder: religious or nonprofit affiliations don’t shield entities that practice rebate arbitrage. That’s simply business compliance 101, though the altruistic branding makes it sting. For a deeper dive into PBM rebate dynamics, see RxPBM.ai.
